BeyondSpring (NASDAQ:BYSI) Trading Up 0% – Time to Buy?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price was up 0% during mid-day trading on Tuesday . The stock traded as high as $0.7556 and last traded at $0.7403. 15,701 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 96,180 shares. The stock had previously closed at $0.74.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of BeyondSpring from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, BeyondSpring has a consensus rating of “Sell”.

BeyondSpring Stock Up 0.0%

The company has a 50 day moving average of $0.86 and a 200 day moving average of $1.35. The firm has a market cap of $30.44 million, a price-to-earnings ratio of -6.17 and a beta of 0.06.

BeyondSpring (NASDAQ:BYSI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.52.

About BeyondSpring

BeyondSpring Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a selective immunomodulating microtubule-destabilizing agent designed to stimulate the immune system while affecting tumor-cell biology.

BeyondSpring has evaluated plinabulin for the prevention of chemotherapy-induced neutropenia, a potentially serious complication of cancer treatment, and for use in combination with other therapies in oncology, including treatment approaches for non-small cell lung cancer.